Last updated on April 2018

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome


Brief description of study

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

Clinical Study Identifier: NCT03495167

Find a site near you

Start Over